70 related articles for article (PubMed ID: 11439321)
1. Neutral effect of valsartan on serum uric acid and renal function tests.
Sayin T; Döven O; Akyürek O ; Dinçer I
J Hum Hypertens; 2001 Jun; 15(6):435-6. PubMed ID: 11439321
[No Abstract] [Full Text] [Related]
2. Effect of valsartan on renal handling of uric acid in healthy subjects.
González-Ortiz M; Mora-Martínez JM; Martínez-Abundis E; Balcázar-Muñoz BR
J Nephrol; 2000; 13(2):126-8. PubMed ID: 10858975
[TBL] [Abstract][Full Text] [Related]
3. Valsartan inhibited the accumulation of dendritic cells in rat fibrotic renal tissue.
Wu K; Zhou T; Sun G; Wang W; Zhang Y; Zhang Y; Hao L; Chen N
Cell Mol Immunol; 2006 Jun; 3(3):213-20. PubMed ID: 16893502
[TBL] [Abstract][Full Text] [Related]
4. [Effects of an angiotensin II receptor antagonist (valsartan) on macro- and microcirculatory hemodynamics of the arm in hypertensive patients].
Marchi SD; Prior M; Zannoni M; Lucchese L; Arosio E
Minerva Cardioangiol; 1999 Dec; 47(12):554-6. PubMed ID: 10670200
[No Abstract] [Full Text] [Related]
5. New basic science initiatives with the angiotensin II receptor blocker valsartan.
de Gasparo M
J Renin Angiotensin Aldosterone Syst; 2000 Jun; 1(2 Suppl):S3-5. PubMed ID: 17199210
[TBL] [Abstract][Full Text] [Related]
6. Effect of valsartan on erythropoietin and hemoglobin levels in stage III-IV chronic kidney disease patients.
Durmus A; Dogan E; Erkoc R; Sayarlioglu H; Topal C; Dilek I
Int J Clin Pract; 2005 Sep; 59(9):1001-4. PubMed ID: 16115171
[TBL] [Abstract][Full Text] [Related]
7. Effects of metronidazole, tinidazole, captopril and valsartan on taste and serum levels of zinc and magnesium.
Salman AA; Ali NA; Jawad AM
Saudi Med J; 2009 Feb; 30(2):209-13. PubMed ID: 19198707
[TBL] [Abstract][Full Text] [Related]
8. Reduction of QTc dispersion by the angiotensin II receptor blocker valsartan may be related to its anti-oxidative stress effect in patients with essential hypertension.
Miyajima K; Minatoguchi S; Ito Y; Hukunishi M; Matsuno Y; Kakami M; Kawasaki M; Nishigaki K; Takemura G; Fujiwara H
Hypertens Res; 2007 Apr; 30(4):307-13. PubMed ID: 17541209
[TBL] [Abstract][Full Text] [Related]
9. Valsartan/hydrochlorothiazide: pharmacology and clinical efficacy.
Kondrack R; Mohiuddin S
Expert Opin Drug Metab Toxicol; 2009 Sep; 5(9):1125-34. PubMed ID: 19689218
[TBL] [Abstract][Full Text] [Related]
10. Effects of perindopril and valsartan on expression of transforming growth factor-beta-Smads in experimental hepatic fibrosis in rats.
Xu W; Song S; Huang Y; Gong Z
J Gastroenterol Hepatol; 2006 Aug; 21(8):1250-6. PubMed ID: 16872305
[TBL] [Abstract][Full Text] [Related]
11. Effects of combined AT1 receptor antagonist/NEP inhibitor on vascular remodeling and cardiac fibrosis in SHRSP.
Pu Q; Brassard P; Javeshghani DM; Iglarz M; Webb RL; Amiri F; Schiffrin EL
J Hypertens; 2008 Feb; 26(2):322-33. PubMed ID: 18192847
[TBL] [Abstract][Full Text] [Related]
12. The angiotensin II receptor antagonist valsartan enhances lipoprotein lipase mass in preheparin serum in type 2 diabetes with hypertension.
Saiki A; Ohira M; Endo K; Koide N; Oyama T; Murano T; Miyashita Y; Shirai K
Diabetes Res Clin Pract; 2006 Dec; 74(3):242-8. PubMed ID: 16713009
[TBL] [Abstract][Full Text] [Related]
13. Effect of angiotensin II on pulse wave velocity in humans is mediated through angiotensin II type 1 (AT(1)) receptors.
Rehman A; Rahman AR; Rasool AH
J Hum Hypertens; 2002 Apr; 16(4):261-6. PubMed ID: 11967720
[TBL] [Abstract][Full Text] [Related]
14. Effect of valsartan compared with valsartan/hydrochlorothiazide on plasma levels of cellular adhesion molecules: the Val-MARC trial.
Conen D; Everett BM; Glynn RJ; Ridker PM
Heart; 2008 Mar; 94(3):e13. PubMed ID: 17923463
[TBL] [Abstract][Full Text] [Related]
15. Valsartan regulates the interaction of angiotensin II type 1 receptor and endothelial nitric oxide synthase via Src/PI3K/Akt signalling.
Su KH; Tsai JY; Kou YR; Chiang AN; Hsiao SH; Wu YL; Hou HH; Pan CC; Shyue SK; Lee TS
Cardiovasc Res; 2009 Jun; 82(3):468-75. PubMed ID: 19307231
[TBL] [Abstract][Full Text] [Related]
16. [The relationship between the gene polymorphism of TGF-beta1 and early renal injury in patients with essential hypertension, and the effect of the gene polymorphism of TGF- beta1 on the individual treatment with valsartan].
Zhao C; Wang YY; Xiao ZX; Wang YP; Zhang QY
Zhonghua Yi Xue Yi Chuan Xue Za Zhi; 2007 Aug; 24(4):428-31. PubMed ID: 17680535
[TBL] [Abstract][Full Text] [Related]
17. Influence of Valsartan on myocardial apoptosis in spontaneously hypertensive rats.
Li W; Sun N; Liu W; Chen Y; Yu Y
Chin Med J (Engl); 2002 Mar; 115(3):364-6. PubMed ID: 11940365
[TBL] [Abstract][Full Text] [Related]
18. Haemodynamic effects of AT1 inhibition and Ca2+-channel blockade in hypertensive patients during isometric stress.
Arosio E; De Marchi S; Prior M; Rigoni A; Lechi A
J Hum Hypertens; 2006 Mar; 20(3):201-5. PubMed ID: 16319906
[TBL] [Abstract][Full Text] [Related]
19. [Hypertension therapy. Does AT-1 blocker help love life?].
MMW Fortschr Med; 2003 Feb; 145(9):57. PubMed ID: 12666537
[No Abstract] [Full Text] [Related]
20. [Lowering of blood pressure, blood pressure amplitude and heart rate by treatment with valsartan or valsartan/hydrochlorothiazide. Results of an open observation study of 11,447 hypertensives].
Weisser B; Vetter H; Mengden T
Dtsch Med Wochenschr; 2003 Mar; 128(11):541-4. PubMed ID: 12635025
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
